ArticleCureus2026
Post-Acute Sequelae of COVID-19 at 12 Months in Hospitalized Patients: A Colombian Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesPost-acute sequelae of SARS-CoV-2 infection (PASC) are a major source of long-term morbidity among COVID-19 survivors, particularly after hospitalization. However, information on PASC prevalence and associated factors at 12 months in Latin America remains limited. This study aimed to estimate the prevalence of PASC at 12 months among hospitalized COVID-19 patients and to identify factors associated with its persistence.
methodsWe conducted an ambidirectional, single-center cohort study including adult patients hospitalized with laboratory-confirmed SARS-CoV-2 infection who completed follow-up evaluations at six and 12 months after discharge. PASC was defined according to the World Health Organization (WHO) criteria. Sociodemographic variables, comorbidities, markers of in-hospital disease severity, and follow-up information were collected using standardized protocols. Statistical analyses included descriptive and bivariate comparisons according to PASC status at 12 months.
resultsAmong 869 hospitalized COVID-19 survivors, the prevalence of PASC at 12 months was 40.7% (n=354). Female sex, markers of severe acute disease, and the presence of PASC at six months were significantly associated with PASC persistence at 12 months. Vaccination coverage at follow-up was high, and although adverse reactions to vaccination were more frequently reported among patients with PASC, no differences in PASC development were observed according to vaccine platform.
conclusionsMore than two out of five patients experienced PASC one year after hospitalization for COVID-19. Associations with severe acute disease and vaccine reactogenicity support the hypothesis that dysregulated host immune responses may contribute to persistent post-COVID symptoms, highlighting the need for early identification and longitudinal follow-up of high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.